Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)

Title: Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)
Authors: Jamaspishvili, Tamara; Patel, Palak G; Niu, Yi; Vidotto, Thiago; Caven, Isabelle; Livergant, Rachel; Fu, Winnie; Kawashima, Atsunari; How, Nathan; Okello, John B; Guedes, Liana B; Ouellet, Veronique; Picanço, Clarissa; Koti, Madhuri; Reis, Rodolfo B; Saad, Fred; Mes-Masson, Anne-Marie; Lotan, Tamara L; Squire, Jeremy A; Peng, Yingwei P; Siemens, D Robert; Berman, David M
Contributors: Prostate Cancer Canada; Movember Foundation; Transformative Pathology Fellowship; Ontario Institute for Cancer Research; Terry Fox Transdisciplinary Fellowship; FAPESP; CNPq Bolsa Produtividade em Pesquisa - Nível: PQ-1B; Terry Fox Research Institute-Canadian Prostate Cancer Biomarker Network; Canadian Institutes for Health Research
Source: JNCI: Journal of the National Cancer Institute ; volume 112, issue 11, page 1098-1104 ; ISSN 0027-8874 1460-2105
Publisher Information: Oxford University Press (OUP)
Publication Year: 2020
Description: Background Phosphatase and tensin homolog (PTEN) loss has long been associated with adverse findings in early prostate cancer. Studies to date have yet to employ quantitative methods (qPTEN) for measuring of prognostically relevant amounts of PTEN loss in postsurgical settings and demonstrate its clinical application. Methods PTEN protein levels were measured by immunohistochemistry in radical prostatectomy samples from training (n = 410) and validation (n = 272) cohorts. PTEN loss was quantified per cancer cell and per tissue microarray core. Thresholds for identifying clinically relevant PTEN loss were determined using log-rank statistics in the training cohort. Univariate (Kaplan-Meier) and multivariate (Cox proportional hazards) analyses on various subpopulations were performed to assess biochemical recurrence-free survival (BRFS) and were independently validated. All statistical tests were two-sided. Results PTEN loss in more than 65% cancer cells was most clinically relevant and had statistically significant association with reduced BRFS in training (hazard ratio [HR] = 2.48, 95% confidence interval [CI] = 1.59 to 3.87; P < .001) and validation cohorts (HR = 4.22, 95% CI = 2.01 to 8.83; P < .001). The qPTEN scoring method identified patients who recurred within 5.4 years after surgery (P < .001). In men with favorable risk of biochemical recurrence (Cancer of the Prostate Risk Assessment – Postsurgical scores
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/jnci/djaa032
DOI: 10.1093/jnci/djaa032/33210617/djaa032.pdf
Availability: https://doi.org/10.1093/jnci/djaa032; http://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djaa032/33210617/djaa032.pdf; http://academic.oup.com/jnci/article-pdf/112/11/1098/34333281/djaa032.pdf
Rights: https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
Accession Number: edsbas.F5FF87F8
Database: BASE